Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 7/20 | 0.49 |
| ▸ | RORC | P51449 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.42 |
| ▸ | PTGER4 | P35408 | 4/20 | 0.42 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.41 |
| ▸ | PDE2A | O00408 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14448627 | 0.91 | MMP13 (0.49) | MMP13SMN1; SMN2POLBALDH1A1LMNA | |
| SCHEMBL14448626 | 0.89 | MMP13 (0.48) | MMP13SMN1; SMN2POLBALDH1A1LMNA | |
| SCHEMBL14448629 | 0.88 | MMP13 (0.54) | MMP13TSHRPDPK1PTGER4SLC22A8 | |
| SCHEMBL14448628 | 0.87 | MMP13 (0.46) | MMP13SMN1; SMN2POLBTSHRPDPK1 | |
| SCHEMBL14448630 | 0.85 | MMP13 (0.52) | MMP13TSHRPDPK1PTGER4SLC22A8 | |
| SCHEMBL14448625 | 0.85 | MMP13 (0.46) | MMP13TSHRPDPK1PTGER4SLC22A8 | |
| SCHEMBL14448658 | 0.85 | MMP13 (0.45) | MMP13SMN1; SMN2POLBALDH1A1LMNA | |
| SCHEMBL14448631 | 0.85 | MMP13 (0.51) | MMP13SMN1; SMN2TSHRPDPK1SLC22A8 | |
| SCHEMBL14448624 | 0.84 | XDH (0.49) | MMP13SMN1; SMN2POLBALDH1A1LMNA | |
| SCHEMBL14448481 | 0.83 | MMP13 (0.55) | MMP13SMN1; SMN2POLBALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070155739-A1 | Substituted bis-amide metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155739-A1 | Substituted bis-amide metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155739-A1 | Substituted bis-amide metalloprotease inhibitors | MMP13, MMP9, ADAMTS13 | MMP13 1/4885RORC 2386/4885SMN1; SMN2 1621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.